Table 3. Comparison between different parameters among groups.
The data has been represented as the number of participants, N, and mean±SD with p-value (p<0.05 considered significant).
P, progression; R, regression; S, stationary; DME, diabetic macular edema; RBS, random blood sugar; HDL, high-density lipoproteins; LDL, low-density lipoproteins; BP, blood pressure
| Systolic BP (N=166) | Diastolic BP (N=166) | ||||||||
| Stage | One way ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value | Stage | One way ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value |
| P | 131.84±17.5 | R | 129.03±13.82 | 0.434 | P | 82.97±7.14 | R | 81.81±9.42 | 0.746 |
| S | 124.20±14.39 | 0.013 | S | 80.86±6.55 | 0.306 | ||||
| DME | 137.50±19.60 | 0.27 | DME | 82.50±7.53 | 0.958 | ||||
| R | 129.03±13.82 | S | 124.20±14.39 | 0.12 | R | 81.81±9.42 | S | 80.86±6.55 | 0.529 |
| DME | 137.50±19.60 | 0.102 | DME | 82.50±7.53 | 0.78 | ||||
| S | 124.20±14.39 | DME | 137.50±19.60 | 0.006 | S | 80.86±6.55 | DME | 82.50±7.53 | 0.479 |
| RBS (N=166) | HbA1c (N=124) | ||||||||
| Stage | One way-ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value | Stage | One way-ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value |
| P | 274.50±79.95 | R | 226.33±85.10 | 0.017 | P | 9.17±1.99 | R | 7.80±1.14 | 0.541 |
| S | 240.65±87.45 | 0.047 | S | 9.90±4.42 | 0.641 | ||||
| DME | 297.58±98.10 | 0.419 | DME | 9.66±2.15 | 0.853 | ||||
| R | 226.33±85.10 | S | 240.65±87.45 | 0.407 | R | 7.80±1.14 | S | 9.90±4.42 | 0.305 |
| DD | 297.58±98.10 | 0.014 | DME | 9.66±2.15 | 0.525 | ||||
| S | 240.65±87.45 | DME | 297.58±98.10 | 0.034 | S | 80.86±6.55 | DME | 9.66±2.15 | 0.921 |
| Serum creatinine (N=105) | HDL (N=105) | ||||||||
| Stage | One way-ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value | Stage | One way-ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value |
| P | 1.04±0.53 | R | 0.95±0.23 | 0.545 | P | 44.66±27.18 | R | 36.10±8.56 | 0.192 |
| S | 0.93±0.24 | 0.232 | S | 35.53±11.30 | 0.028 | ||||
| DME | 1.25±0.96 | 0.23 | DME | 45.12±23.76 | 0.949 | ||||
| R | 0.95±0.23 | S | 0.93±0.24 | 0.878 | R | 36.10±8.56 | S | 35.53±11.30 | 0.925 |
| DME | 1.25±0.96 | 0.137 | DME | 45.12±23.76 | 0.283 | ||||
| S | 0.93±0.24 | DME | 1.25±0.96 | 0.045 | S | 35.53±11.30 | DME | 45.12±23.76 | 0.031 |
| LDL (N=105) | Triglycerides (N=105) | ||||||||
| Stage | One way-ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value | Stage | One way-ANOVA (mean±SD) | Stage | Post-hoc Tukey’s test (mean±SD) | P-value |
| P | 114.11±42.34 | R | 108.90±25.75 | 0.743 | P | 208.85±174.15 | R | 213.10±109.82 | 0.926 |
| S | 124.61±43.91 | 0.292 | S | 188.70±97.36 | 0.474 | ||||
| DME | 125.50±51.88 | 0.51 | DME | 199.87±54.56 | 0.854 | ||||
| R | 108.90±25.75 | S | 124.61±43.91 | 0.285 | R | 213.10±109.82 | S | 188.70±97.36 | 0.558 |
| DME | 125.50±51.88 | 0.416 | DME | 199.87±54.56 | 0.819 | ||||
| S | 124.61±43.91 | DME | 125.50±51.88 | 0.956 | S | 188.70±97.36 | DME | 199.87±54.56 | 0.807 |